At the news
? NEUTRALIMPACT 3/10 SC 13G filed Nov 5, 2026 at 13:27 ET
FMR LLC (Fidelity) filed a Schedule 13G disclosing a 6.4% passive stake in Tarsus Pharmaceuticals as of September 30, 2026, representing 3,143,158.20 shares. This is a new filing (not an amendment) and certifies passive intent with no control or influence purpose. The disclosure follows Tarsus' Q3 2026 earnings report showing strong XDEMVY revenue growth of ~64% YoY to $194.6 million.
- FMR LLC (Fidelity) filed a new Schedule 13G disclosing beneficial ownership of 3,143,158.20 shares of Tarsus Pharmaceuticals common stock
- Stake represents 6.4% of shares outstanding as of September 30, 2026
- Filing certifies passive intent under Rule 13d-1(b) with no purpose of changing or influencing control
- Filing date is November 5, 2026, with ownership measured as of September 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access